Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062463 | 0.90 | ADORA1 (0.40) | ADORA1SMPD1LGALS3 | |
| SCHEMBL4899187 | 0.86 | ADORA1 (0.38) | ADORA1SMPD1 | |
| SCHEMBL6334894 | 0.80 | LGALS3 (0.41) | LGALS3 | |
| SCHEMBL2511743 | 0.75 | FBP1 (0.53) | — | |
| SCHEMBL3229780 | 0.71 | ADORA1 (0.38) | ADORA1CYP2C19HIF1A | |
| SCHEMBL783243 | 0.70 | LGALS8 (0.41) | ADORA1SMPD1 | |
| SCHEMBL2045173 | 0.70 | SMPD1 (0.45) | ADORA1SMPD1 | |
| SCHEMBL851492 | 0.70 | SMPD1 (0.45) | SMPD1 | |
| SCHEMBL4596697 | 0.69 | SMPD1 (0.48) | SMPD1 | |
| SCHEMBL5378658 | 0.69 | SMPD1 (0.48) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009128644-A9 | GENOME-SCALE BUTANOL-PRODUCING MICROORGANISM METABOLIC NETWORK MODEL AND METHODS USING THE SAME FOR ANALYSIS OF METABOLIC CHARACTERISTICS OF BUTANOL-PRODUCING MICROORGANISMS AND FOR SCREENING DELETION TARGETS | 한국과학기술원 (KR) | 2010-04-15 | — | — | WO | claimed |
| US-20100047396-A1 | METHOD FOR OBTAINING VARIANTS OF LACTIC ACID BACTERIA USABLE FOR PRODUCING VITAMIN K2 AND APPLICATION TO THE PREPARATION OF FOOD PRODUCTS | COMPAGNIE GERVAIS DANONE (FR) | 2010-02-25 | — | — | US | claimed |
| WO-2009128644-A2 | GENOME-SCALE BUTANOL-PRODUCING MICROORGANISM METABOLIC NETWORK MODEL AND METHODS USING THE SAME FOR ANALYSIS OF METABOLIC CHARACTERISTICS OF BUTANOL-PRODUCING MICROORGANISMS AND FOR SCREENING DELETION TARGETS | 한국과학기술원 (KR) | 2009-10-22 | — | — | WO | claimed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | claimed |
| US-20240173352-A1 | CELL-SURFACE RECEPTORS RESPONSIVE TO LOSS OF HETEROZYGOSITY | A2 BIOTHERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240101967-A1 | COMPOSITIONS AND METHODS FOR GENE EDITING WITH WOOLLY MAMMOTH ALLELES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240075067-A1 | COMPOSITIONS AND METHODS FOR TREATING HER2 POSITIVE CANCERS | A2 BIOTHERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230393122-A1 | STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF | Centre for Translational Stem Cell Biology Limited (CN) | 2023-12-07 | — | — | US | disclosed |
| US-11815509-B2 | Cell line and uses thereof | SENZAGEN AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11746368-B1 | Lactococcus lactis subsp. lactis A32, derived product and use thereof | QILU UNIVERSITY OF TECHNOLOGY (CN) | 2023-09-05 | — | — | US | disclosed |
| WO-2004048938-A2 | METHODS OF DETECTING SOFT TISSUE SARCOMA, COMPOSITIONS AND METHODS OF SCREENING FOR SOFT TISSUE SARCOMA MODULATORS | PROTEIN DESIGN LABS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| CN-1452659-A | Corynebacterium glutamicum genes encoding metabolic pathway proteins | BASF AG (DE) | 2003-10-29 | — | — | CN | disclosed |
| US-6583266-B1 | Peptide for use in the diagnosis and treatment of skin disorders and tuberculosis | GENOME THERAPEUTICS CORPORATION | 2003-06-24 | — | — | US | disclosed |
| WO-2003022987-A2 | METHODS OF DIAGNOSIS OF HEPATITIS C INFECTION, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF HEPATITIS C INFECTION | EOS BIOTECHNOLOGY, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| CN-1371417-A | Corynebacterium glutamicum genes encoding metabolic pathway proteins | BASF AG (DE) | 2002-09-25 | — | — | CN | disclosed |
| WO-2002042478-A2 | NEMATODE RESISTANT PLANT | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6348582-B1 | NUCLEOTIDE SEQUENCE FROM STAPHYLOCOCCUS AUREUS; PROBES; PRIMERS; DIAGNOSIS OF INFECTIONS; DRUG SCREENING OF BACTERIOSTATS AND BACTERICIDES | SMITHKLINE BEECHAM CORPORATION | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | ABL2, ABL1, VAV1 | ADORA1 4510/4885SMPD1 533/4885LGALS3 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.